APOE2 allele increased in tardive dyskinesia.
APOE2 allele increased in tardive dyskinesia.
复制标题
APOE2 等位基因在迟发性运动障碍中增加。
DOI：
10.1002/mds.20768
复制
发表时间：
2006
期刊：
影响因子：
--
通讯作者：
Morgenlander,JoelC
中科院分区：
文献类型：
--
作者：
Halford,Jonathan;Mazeika,Gandis;Slifer,Susan;Speer,Marcy;Saunders,AnnM;Strittmatter,WarrenJ;Morgenlander,JoelC
研究了97例迟发性运动障碍住院患者（平均AIMS评分= 13），其中大多数为精神分裂症患者。40例患者为白人，57例为非洲裔美国人。将这些患者的APOE基因型与先前发表的对照基因型以及先前发表的精神分裂症患者APOE基因型研究进行比较。非裔美国人迟发性运动障碍人群和非裔美国人对照组的APOE等位基因频率无显著差异。相比之下，当比较等位基因频率和基因型频率时，将白种人迟发性运动障碍人群与白种人对照进行比较，获得了显著（< 0.05）P值。这项研究表明，携带APOE2等位基因的高加索人患迟发性运动障碍的风险增加，而非洲裔美国人则没有。APOE基因型特异性迟发性运动障碍和阿尔茨海默病的风险在人群中各不相同，可能是由于招募患者或对照，也可能是由于不同遗传或环境背景的修饰效应。APOE2等位基因增加迟发性运动障碍风险的机制尚不清楚。关于迟发性运动障碍风险增加机制的进一步信息可能导致处方实践分层，权衡药物成本与副作用的相对风险。© 2005运动障碍协会
Ninety‐seven inpatients with tardive dyskinesia (average AIMS score = 13), the majority of whom were schizophrenic, were studied. Forty patients were Caucasian, and 57 were African–American. The APOE genotypes of these patients were compared to previously published genotypes of controls and with previously published studies of APOE genotypes in patients with schizophrenia. There were no significant differences in APOE allele frequencies comparing the African–American tardive dyskinesia population and the African–American control groups. In contrast, significant (< 0.05)Pvalues were obtained comparing the Caucasian tardive dyskinesia population to the Caucasian controls, when comparing allele frequencies and genotypic frequencies. This study suggests that Caucasians bearing an APOE2 allele are at increased risk of developing tardive dyskinesia, whereas African–Americans are not. APOE genotype‐specific risks of both tardive dyskinesia and Alzheimer's disease that vary across populations could be due to recruitment of patients or controls or could be due to modifying effects of differing genetic or environmental backgrounds. The mechanism by which the APOE2 allele increases risk of tardive dyskinesia is not known. Further information about the mechanisms of increased risk of tardive dyskinesia could result in stratification of prescribing practices weighing the costs of medications against the relative risk of side effects. © 2005 Movement Disorder Society